VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
VBIV was delisted on the 7th of August, 2024.
111 hedge funds and large institutions have $36.7M invested in VBI Vaccines, Inc. New Common Stock (Canada) in 2022 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 26 increasing their positions, 42 reducing their positions, and 26 closing their positions.
7,200% more call options, than puts
Call options by funds: $146K | Put options by funds: $2K
13% less funds holding
Funds holding: 127 → 111 (-16)
38% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 42
48% less capital invested
Capital invested by funds: $69.9M → $36.7M (-$33.3M)
58% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$114K |
| 2 |
Jane Street
New York
|
+$104K |
| 3 |
YIH
Y-Intercept (HK)
Hong Kong
|
+$98.5K |
| 4 |
E
Ergoteles
New York
|
+$86.6K |
| 5 |
JP Morgan Chase
New York
|
+$79.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$480K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$441K |
| 3 |
Millennium Management
New York
|
-$429K |
| 4 |
State Street
Boston,
Massachusetts
|
-$416K |
| 5 |
Swiss National Bank
Zurich,
Switzerland
|
-$322K |
VBIV Hedge Fund Activity: Q4 2022 in Review
111 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) for Q4 2022, worth a combined $36.7M — down 48% from $69.9M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of VBIV and 11 opened new positions — a net loss of 15 holders — while 42 trimmed existing stakes and 26 added.
The largest buyer was Cambridge Investment Research Advisors, adding an estimated $114K. The largest seller was Invesco, cutting an estimated $480K.
- 111 institutional investors held VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) as of Q4 2022, down from 127 in Q3 2022.
- Funds reported $36.7M of VBI Vaccines, Inc. New Common Stock (Canada) stock for Q4 2022, down 48% quarter-over-quarter.
- 11 funds opened new VBI Vaccines, Inc. New Common Stock (Canada) positions in Q4 2022 and 26 closed out, a net change of -15 holders.
- The largest VBI Vaccines, Inc. New Common Stock (Canada) buyer in Q4 2022 was Cambridge Investment Research Advisors, an estimated $114K added.
- The largest VBI Vaccines, Inc. New Common Stock (Canada) seller in Q4 2022 was Invesco, an estimated $480K sold.
Based on aggregated 13F filings for Q4 2022.